KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

Cortes, J.Cescon, D. W.Rugo, H. S.Im, S-A.Yusof, M. MdGallardo, C.Lipatov, O.2023-01-122023-01-1220210923-75341569-8041https://doi.org/10.1016/j.annonc.2021.08.2089https://hdl.handle.net/11454/76401Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 16-21, 2021 -- ELECTR NETWORK[No Abstract Available]en10.1016/j.annonc.2021.08.2089info:eu-repo/semantics/openAccessKEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBCConference Object32S1289S1290WOS:000700527703488Q1